This represents a 9% discount to the volume weighted average share price in the 15 days leading up to and including the date of the placement.
Shareholders on the register as at 9 March 9, 2018, will also be entitled to acquire up to $15,000 worth of new shares at the placement price.
Well supported by leading institutions
Former Immutep chairman Lucy Turnbull and US healthcare institutional investors, including Ridgeback Capital Investments, also supported the raising.
Funds applied to immuno-oncology development programs
Funds will be used to support Immutep’s ongoing and planned immuno-oncology clinical development programs and its pre-clinical program in autoimmune disease.
Immutep’s current lead product is eftilagimod alpha, which plays a vital role in the regulation of the T cell immune response.
Eftilagimod alpha, alone or in combination with other therapeutics, has completed early Phase II trials, boosting T cell responses for cancer chemo-immunotherapy.